141 related articles for article (PubMed ID: 37251313)
1. Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19.
Lu J; Cai H; Hao Y; Lin Z; Liu S; Zhan Y; Ding L; Huang M; Li Z; Xu L; Yan X; Yang L; Zhang H; Zhang W; Zhao L; Zhao J; Wang T; Gu L
Front Pharmacol; 2023; 14():1161897. PubMed ID: 37251313
[No Abstract] [Full Text] [Related]
2. Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness: A Real-World Study.
Chen X; Zhu Y; Shen L; Zhou D; Feng N; Tong Q
J Intensive Care Med; 2024 Feb; ():8850666241228841. PubMed ID: 38356292
[No Abstract] [Full Text] [Related]
3. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis.
Lingscheid T; Kinzig M; Krüger A; Müller N; Bölke G; Tober-Lau P; Münn F; Kriedemann H; Witzenrath M; Sander LE; Sörgel F; Kurth F
Antimicrob Agents Chemother; 2022 Nov; 66(11):e0122922. PubMed ID: 36286542
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal Impairment.
Toussi SS; Neutel JM; Navarro J; Preston RA; Shi H; Kavetska O; LaBadie RR; Binks M; Chan PLS; Demers N; Corrigan B; Damle B
Clin Pharmacol Ther; 2022 Oct; 112(4):892-900. PubMed ID: 35712797
[TBL] [Abstract][Full Text] [Related]
5. Low Nirmatrelvir and Ritonavir Exposure through Breastmilk: Analyzing Milk Concentrations and Infant Risk.
Dai J; Fuquay T; Huseman S; Patel D; Datta P; Krutsch K
Clin Pharmacol Ther; 2024 Jun; ():. PubMed ID: 38923506
[TBL] [Abstract][Full Text] [Related]
6. Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge.
Yan J; Cai H; Wang J; Zhu M; Li P; Li P; Wu B; Che X; Gu L; Mou S
Front Pharmacol; 2023; 14():1147980. PubMed ID: 37033654
[No Abstract] [Full Text] [Related]
7. Nirmatrelvir-ritonavir treatment of COVID-19 in a high-risk patient population: A retrospective observational study.
Kane AM; Keenan EM; Lee K; Hartkopf KJ; Ludwig TA; Trapskin PJ; Vanderloo JP; Schulz LT
J Am Coll Clin Pharm; 2023 Jan; 6(1):29-33. PubMed ID: 36718381
[TBL] [Abstract][Full Text] [Related]
8. A retrospective cohort study of prescribing outcomes in outpatients treated with nirmatrelvir-Ritonavir for COVID-19 in an interdisciplinary community clinic.
Leung V; Gill S; Llanes A; Khawaja A; Stagg A; McCready J; Jacubovich M; Ho G; Powis J; Kandel C
PLoS One; 2023; 18(10):e0293302. PubMed ID: 37856531
[TBL] [Abstract][Full Text] [Related]
9. Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study.
Spiliopoulou V; Ntanasis-Stathopoulos I; Malandrakis P; Gavriatopoulou M; Theodorakakou F; Fotiou D; Migkou M; Roussou M; Eleutherakis-Papaiakovou E; Kastritis E; Dimopoulos MA; Terpos E
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992413
[TBL] [Abstract][Full Text] [Related]
10. Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study.
Zhao Q; Zheng B; Han B; Feng P; Xia Z; Jiang H; Ying Y; Zhu J; Fei C; Xiang J; Shen L; Luo Q; Wu Y; Wusiman A; Xin C; Zhang M; Li G; Li X
Infect Dis Ther; 2023 Aug; 12(8):2087-2102. PubMed ID: 37486556
[TBL] [Abstract][Full Text] [Related]
11. Short-term Pregnancy Outcomes After Nirmatrelvir-Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19).
Loza A; Farias R; Gavin N; Wagner R; Hammer E; Shields A
Obstet Gynecol; 2022 Sep; 140(3):447-449. PubMed ID: 36356238
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes.
Ma BH; Yip TC; Lui GC; Lai MS; Hui E; Wong VW; Tse YK; Chan HL; Hui DS; Kwok TC; Wong GL
JAMA Netw Open; 2023 Apr; 6(4):e2310887. PubMed ID: 37103932
[TBL] [Abstract][Full Text] [Related]
13. A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19.
Tomida T; Itohara K; Yamamoto K; Kimura T; Fujita K; Uda A; Kitahiro Y; Yokoyama N; Hyodo Y; Omura T; Yano I
Drug Metab Pharmacokinet; 2023 Dec; 53():100529. PubMed ID: 37924724
[TBL] [Abstract][Full Text] [Related]
14. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants.
Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L
Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224
[TBL] [Abstract][Full Text] [Related]
15. Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching.
Wei AH; Zeng L; Wang L; Gui L; Zhang WT; Gong XP; Li J; Liu D
Front Pharmacol; 2023; 14():1274294. PubMed ID: 37900159
[No Abstract] [Full Text] [Related]
16. Population-based evaluation of the effectiveness of nirmatrelvir-ritonavir for reducing hospital admissions and mortality from COVID-19.
Schwartz KL; Wang J; Tadrous M; Langford BJ; Daneman N; Leung V; Gomes T; Friedman L; Daley P; Brown KA
CMAJ; 2023 Feb; 195(6):E220-E226. PubMed ID: 36781188
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Clinical Outcomes of Pregnant Patients Treated With Nirmatrelvir and Ritonavir for Acute SARS-CoV-2 Infection.
Garneau WM; Jones-Beatty K; Ufua MO; Mostafa HH; Klein SL; Burd I; Gebo KA
JAMA Netw Open; 2022 Nov; 5(11):e2244141. PubMed ID: 36445705
[TBL] [Abstract][Full Text] [Related]
18. The Impacts of Nirmatrelvir-Ritonavir on Myocardial Injury and Long-Term Cardiovascular Outcomes in Hospitalized Patients with COVID-19 amid the Omicron Wave of the Pandemic.
Gu J; Han ZH; Wang CQ; Zhang JF
Cardiovasc Drugs Ther; 2024 Mar; ():. PubMed ID: 38466547
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19.
Hu CY; Cui WS; Lei Y; Tang YW; Zhang YY; Su QM; Peng F; Zeng YF; Song JL; Luo CN; Zhou Y; Li XY; Zhao ZX
Infect Drug Resist; 2023; 16():7797-7808. PubMed ID: 38148771
[TBL] [Abstract][Full Text] [Related]
20. Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS.
Li M; Zhang QS; Liu XL; Wang HL; Liu W
Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]